JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 31 No. 1 118-122
© 1990 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ballinger, J. R.
Right arrow Articles by Reid, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ballinger, J. R.
Right arrow Articles by Reid, R. H.

Radiopharmaceutical Factors in the Variable Quality of [99mTc]HM-PAO Images of the Brain

James R. Ballinger, Karen Y. Gulenchyn and Robert H. Reid

Division of Nuclear Medicine, Ottawa Civic Hospital, Ottawa, Canada

Correspondence: For reprints contact: J. R. Ballinger, PhD, Div. of Nuclear Medicine, Ottawa Civic Hospital, 1053 Carling Ave., Ottawa, Ontario, Canada, K1Y 4E9.

ABSTRACT

Variability in the quality of [99mTc]HM-PAO images of the brain has been attributed to differences between kits and the addition of excessive amounts of pertechnetate to the kits. A retrospective study showed no significant differences between batches of kits with respect to radiochemical purity (RCP) or image quality. Up to 3000 MBq (81 mCi) pertechnetate could be added to the kit without adversely affecting RCP or image quality. It was shown that image quality was directly affected by RCP at time of injection and dropped sharply when RCP fell below 85%. Interstitial injection and mixing with blood prior to injection also resulted in poor image quality. Pretreatment with perchlorate reduced uptake of activity in the parotid glands; this improved image quality and reduced the influence of RCP.




This article has been cited by other articles:


Home page
J. Nucl. Med. Technol.Home page
I. L. Koslowsky, S. E. Brake, and S. J. Bitner
Evaluation of the Stability of 99mTc-ECD and Stabilized 99mTc-HMPAO Stored in Syringes
J. Nucl. Med. Technol., December 1, 2001; 29(4): 197 - 200.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. Roca, F. Iglesias, V. García, F. Armero, and M C. Díaz
Chemotaxis, Viability, and Labeling Stability of Leukocytes Labeled with 99mTc-Exametazime Stabilized with Methylene Blue
J. Nucl. Med., March 1, 2001; 42(3): 505 - 508.
[Abstract] [Full Text]


Home page
Pharmacol. Rev.Home page
J. Wolff
Perchlorate and the Thyroid Gland
Pharmacol. Rev., March 1, 1998; 50(1): 89 - 106.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1990 by the Society of Nuclear Medicine.